Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT03085056
Phase
EARLY_PHASE1
Status
Active Not Recruiting

Conditions

  • Anaplastic Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trametinib — DRUG
    trametinib orally 2mg daily during each 4 week cycle
  • Paclitaxel — DRUG
    paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks

Study Details

The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.

Key Dates

Start date
Mar 15, 2017
Status verified
Jul 2025
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
13 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Trametinib in Combination With Paclitaxel
    Patients will receive paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks, which is a standard regimen in the treatment of anaplastic thyroid cancer, in combination with trametinib 2mg daily during each 4 week cycle.

Primary Outcome Measure

Progression-Free Survival (PFS) [ Time Frame: 6 months ]

Locations (7)

Find similar trials in Basking Ridge, NJ

Related Studies